Home / Conditions / Medial Meniscus Tear
Medial Meniscus Tear: when insurers say no, reviewers often say yes
In 29 published external-review decisions involving medial meniscus tear, independent physician reviewers overturned the insurer’s denial 34.5% of the time.
Published decisions
29
2001–2026
Overturned
34.5%
10 denials reversed
Most-fought treatments for medial meniscus tear
What insurers denied — and how those fights ended.
| Category | Decisions | Overturned |
|---|---|---|
| Knee Arthroscopy | 3 | 0% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 21 | 42.9% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 8 | 12.5% |
Typical time to a decision
16 days
Most land between 5 and 21 days
Handled as urgent
37.9%
Expedited when a delay would cause harm
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Euflexxa injections. The Health Plan has denied this request indicating that the requested treatment is not medically necessary for treatment of the enrollee’s knee pain. A review of the record indicates that the enrollee has been diagnosed with osteoarthritis, essential hypertension, and morbid obesity. A visit note dated 11/2/18, reported the enrollee presented with bilateral knee pain, right more than left. The provider reported previous magnetic resonance imaging of the right knee revealed significant diffuse meniscus tear of the medial meniscus; and chondromalacia to the medial compartment, mild to moderate chondromalacia to the patella and a partial tear of the anterior cruciate ligament (ACL).
Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for platelet-rich plasma (PRP) injections for the right knee. This patient sustained a right knee injury and was diagnosed with a grade 3 medial collateral ligament (MCL) tear, anterior cruciate ligament (ACL) tear, medial meniscus tear, and lateral meniscus tear. She underwent ACL reconstruction with medial and lateral meniscus repair. Surgical augmentation with PRP was given as the MCL and meniscal capsular junction were not repaired surgically. A subsequent PRP injection was performed to the posterior lateral corner ligaments including popliteus, arcuate ligament, popliteal fibular ligament, and fibular collateral ligament.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Physician 1: The patient is a 24-year-old male that injured his left knee in October 2004 while playing soccer. Radiographic studies demonstrated a complete tear of the anterior cruciate ligament (ACL) and a bucket handle tear of the medial meniscus. The patient underwent left knee ACL reconstruction in October 2005. The operative report noted the medial meniscus was too damaged for repair and it was debrided with a near complete medial meniscectomy. There was also a posterior horn lateral meniscus tear that was debrided. As of May 2006 X-ray identified mild degenerative changes within the medial compartment however, the patient had no instability. The orthopedist noted the patient was currently asymptomatic. In September 2006 the provider noted the patient continued to do well with relatively no pain or instability, but he had occasional mild pain with descending stairs.
A 49-year-old female enrollee has requested reimbursement and prospective authorization and coverage for Apheresis Plasma Therapeutic treatments over a 4-month period .for treatment of the enrollee’s right knee meniscus tear. Findings: Three physician reviewers found that a magnetic resonance imaging (MRI) imaging scan was interpreted to show a recurrent torn medial meniscus 1 cm complex. The patient has been treated with viscosupplementation with Synvisc, opioids and steroid local injections. On physical examination a month prior to the dates in question, the patient reported that the right knee Synvisc injection from seven months prior did not offer her much symptomatic relief. On that date, the patient’s current medications included Flexeril, Celebrex, Percocet, Metoprolol, Pristiq, and Zoloft.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
How to use this in your appeal
These outcomes come from California’s external review program — an independent physician panel whose decision binds the insurer. Every state has an equivalent, and internal appeals succeed even more often. If your care for medial meniscus tear was denied, the published record says the denial is worth fighting.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.